Sanofi (SNY) Sees Slight Pessimism From Analysts

We recently published 13 Best ADR Stocks to Invest In.  Sanofi (NASDAQ:SNY) is one of the best ADR stocks.

Sanofi (NASDAQ:SNY) is a French pharmaceutical firm that has been at the center of several analysts’ attention lately. One such coverage came from Guggenheim on December 9th after the firm cut its stock rating to Neutral from Buy and removed its share price target. As per the details, the research firm’s latest sentiment for Sanofi (NASDAQ:SNY) is based on a changed outlook about the pharma company’s drug pipeline as it believes that Sanofi does not have any significant catalysts in its pipeline for the time being.

However, while Guggenheim might be doubtful, Sanofi (NASDAQ:SNY) is making moves to expand its pipeline. On December 4th, the firm announced that it had completed the acquisition of British biotechnology company Vicebio Limited. Through the deal, Sanofi (NASDAQ:SNY) aims to grow its presence in the market for respiratory vaccines. The firm also scored a win in the European Union in November after it, along with Regeneron, secured approval from the European Commission for their Dupixent (dupilumab) drug to treat and manage hives. The approval came after phase three trials of the treatment, and Regeneron’s President and CSO, underscored its importance by commenting that the drug represented ” first innovation for patients with this disease in over a decade.”

While we acknowledge the potential of SNY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.